07-05-2025
Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) — Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform targeting the intersection of metabolism, immunity, and neurodegeneration, today announced the appointment of Adrian Noriega, M.D., Ph.D., to its senior scientific advisory board. Dr. Noriega's expertise in Alzheimer's disease, vascular neurology, and biomarker-driven strategy marks a key milestone in Pramana's neurodegenerative expansion.
With this appointment, Pramana further strengthens its world-class scientific team spanning metabolic disease, cardiovascular biology, and neurology. Together, this group is advancing a bold vision: to transform chronic disease treatment using a first-in-class, oral GPR119 agonists designed as 'smart molecules' for glycemic control and beyond.
